COVID-19 Impact on Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, Status and Forecast 2020-2026

September 2020 | 92 pages | ID: CF43468013A1EN
QYResearch

Abstracts

This report focuses on the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Active Biotech Ab
• Amgen
• Bayer AG
• Cipla Limited
• Roche Holding AG
• Glaxosmithkline Plc
• Novartis Ag
• Pfizer, Inc.

Market segment by Type, the product can be split into

• Afinitor (Everolimus)
• Avastin (Bevacizumab)
• Cabomety (Cabozantinib)
• Inlyta (Axitinib)
• Nexavar (Sorafenib)
• Proleukin (Aldesleukin)
• Torisel (Temsirolimus)
• Sutent (Sunitinib)
• Votrient (Pazopanib)

Market segment by Application, split into

• Hospitals
• Clinic
• Others

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs status, future forecast, growth opportunity, key market and key players.
• To present the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue
1.4 Market Analysis by Type
  1.4.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Afinitor (Everolimus)
  1.4.3 Avastin (Bevacizumab)
  1.4.4 Cabomety (Cabozantinib)
  1.4.5 Inlyta (Axitinib)
  1.4.6 Nexavar (Sorafenib)
  1.4.7 Proleukin (Aldesleukin)
  1.4.8 Torisel (Temsirolimus)
  1.4.9 Sutent (Sunitinib)
  1.4.10 Votrient (Pazopanib)
1.5 Market by Application
  1.5.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application: 2020 VS 2026
  1.5.2 Hospitals
  1.5.3 Clinic
  1.5.4 Others
1.6 Coronavirus Disease 2019 (Covid-19): Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Industry Impact
  1.6.1 How the Covid-19 is Affecting the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Industry
    1.6.1.1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Perspective (2015-2026)
2.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Growth Trends by Regions
  2.2.1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Historic Market Share by Regions (2015-2020)
  2.2.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Strategy
  2.3.6 Primary Interviews with Key Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Market Size
  3.1.1 Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Revenue (2015-2020)
  3.1.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Players (2015-2020)
  3.1.3 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Concentration Ratio
  3.2.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in 2019
3.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players Head office and Area Served
3.4 Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Solution and Service
3.5 Date of Enter into Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Historic Market Size by Type (2015-2020)
4.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Type (2021-2026)

5 KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020)
5.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2015-2020)
6.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in North America (2019-2020)
6.3 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020)
6.4 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2015-2020)
7.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in Europe (2019-2020)
7.3 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020)
7.4 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020)

8 CHINA

8.1 China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2015-2020)
8.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in China (2019-2020)
8.3 China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020)
8.4 China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2015-2020)
9.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in Japan (2019-2020)
9.3 Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020)
9.4 Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2015-2020)
10.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020)

11 INDIA

11.1 India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2015-2020)
11.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in India (2019-2020)
11.3 India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020)
11.4 India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2015-2020)
12.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020)
12.4 Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Active Biotech Ab
  13.1.1 Active Biotech Ab Company Details
  13.1.2 Active Biotech Ab Business Overview and Its Total Revenue
  13.1.3 Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
  13.1.4 Active Biotech Ab Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020))
  13.1.5 Active Biotech Ab Recent Development
13.2 Amgen
  13.2.1 Amgen Company Details
  13.2.2 Amgen Business Overview and Its Total Revenue
  13.2.3 Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
  13.2.4 Amgen Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
  13.2.5 Amgen Recent Development
13.3 Bayer AG
  13.3.1 Bayer AG Company Details
  13.3.2 Bayer AG Business Overview and Its Total Revenue
  13.3.3 Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
  13.3.4 Bayer AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
  13.3.5 Bayer AG Recent Development
13.4 Cipla Limited
  13.4.1 Cipla Limited Company Details
  13.4.2 Cipla Limited Business Overview and Its Total Revenue
  13.4.3 Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
  13.4.4 Cipla Limited Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
  13.4.5 Cipla Limited Recent Development
13.5 Roche Holding AG
  13.5.1 Roche Holding AG Company Details
  13.5.2 Roche Holding AG Business Overview and Its Total Revenue
  13.5.3 Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
  13.5.4 Roche Holding AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
  13.5.5 Roche Holding AG Recent Development
13.6 Glaxosmithkline Plc
  13.6.1 Glaxosmithkline Plc Company Details
  13.6.2 Glaxosmithkline Plc Business Overview and Its Total Revenue
  13.6.3 Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
  13.6.4 Glaxosmithkline Plc Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
  13.6.5 Glaxosmithkline Plc Recent Development
13.7 Novartis Ag
  13.7.1 Novartis Ag Company Details
  13.7.2 Novartis Ag Business Overview and Its Total Revenue
  13.7.3 Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
  13.7.4 Novartis Ag Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
  13.7.5 Novartis Ag Recent Development
13.8 Pfizer, Inc.
  13.8.1 Pfizer, Inc. Company Details
  13.8.2 Pfizer, Inc. Business Overview and Its Total Revenue
  13.8.3 Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
  13.8.4 Pfizer, Inc. Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
  13.8.5 Pfizer, Inc. Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue
Table 3. Ranking of Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Afinitor (Everolimus)
Table 6. Key Players of Avastin (Bevacizumab)
Table 7. Key Players of Cabomety (Cabozantinib)
Table 8. Key Players of Inlyta (Axitinib)
Table 9. Key Players of Nexavar (Sorafenib)
Table 10. Key Players of Proleukin (Aldesleukin)
Table 11. Key Players of Torisel (Temsirolimus)
Table 12. Key Players of Sutent (Sunitinib)
Table 13. Key Players of Votrient (Pazopanib)
Table 14. COVID-19 Impact Global Market: (Four Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Forecast Scenarios)
Table 15. Opportunities and Trends for Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players in the COVID-19 Landscape
Table 16. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 17. Key Regions/Countries Measures against Covid-19 Impact
Table 18. Proposal for Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players to Combat Covid-19 Impact
Table 19. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 20. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 21. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 22. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Regions (2015-2020)
Table 23. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 24. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Regions (2021-2026)
Table 25. Market Top Trends
Table 26. Key Drivers: Impact Analysis
Table 27. Key Challenges
Table 28. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Strategy
Table 29. Main Points Interviewed from Key Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players
Table 30. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Players (2015-2020) (Million US$)
Table 31. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Players (2015-2020)
Table 32. Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs as of 2019)
Table 33. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 34. Key Players Headquarters and Area Served
Table 35. Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Solution and Service
Table 36. Date of Enter into Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market
Table 37. Mergers & Acquisitions, Expansion Plans
Table 38. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$)
Table 39. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Share by Type (2015-2020)
Table 40. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Type (2021-2026)
Table 41. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Share by Application (2015-2020)
Table 42. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$)
Table 43. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Share by Application (2021-2026)
Table 44. North America Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (2019-2020) (Million US$)
Table 45. North America Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share (2019-2020)
Table 46. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$)
Table 47. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2015-2020)
Table 48. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$)
Table 49. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2015-2020)
Table 50. Europe Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (2019-2020) (Million US$)
Table 51. Europe Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share (2019-2020)
Table 52. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$)
Table 53. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2015-2020)
Table 54. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$)
Table 55. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2015-2020)
Table 56. China Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (2019-2020) (Million US$)
Table 57. China Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share (2019-2020)
Table 58. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$)
Table 59. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2015-2020)
Table 60. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$)
Table 61. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2015-2020)
Table 62. Japan Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (2019-2020) (Million US$)
Table 63. Japan Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share (2019-2020)
Table 64. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$)
Table 65. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2015-2020)
Table 66. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$)
Table 67. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2015-2020)
Table 68. Southeast Asia Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (2019-2020) (Million US$)
Table 69. Southeast Asia Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share (2019-2020)
Table 70. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$)
Table 71. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2015-2020)
Table 72. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$)
Table 73. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2015-2020)
Table 74. India Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (2019-2020) (Million US$)
Table 75. India Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share (2019-2020)
Table 76. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$)
Table 77. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2015-2020)
Table 78. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$)
Table 79. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2015-2020)
Table 80. Central & South America Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (2019-2020) (Million US$)
Table 81. Central & South America Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share (2019-2020)
Table 82. Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$)
Table 83. Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2015-2020)
Table 84. Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$)
Table 85. Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2015-2020)
Table 86. Active Biotech Ab Company Details
Table 87. Active Biotech Ab Business Overview
Table 88. Active Biotech Ab Product
Table 89. Active Biotech Ab Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$)
Table 90. Active Biotech Ab Recent Development
Table 91. Amgen Company Details
Table 92. Amgen Business Overview
Table 93. Amgen Product
Table 94. Amgen Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$)
Table 95. Amgen Recent Development
Table 96. Bayer AG Company Details
Table 97. Bayer AG Business Overview
Table 98. Bayer AG Product
Table 99. Bayer AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$)
Table 100. Bayer AG Recent Development
Table 101. Cipla Limited Company Details
Table 102. Cipla Limited Business Overview
Table 103. Cipla Limited Product
Table 104. Cipla Limited Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$)
Table 105. Cipla Limited Recent Development
Table 106. Roche Holding AG Company Details
Table 107. Roche Holding AG Business Overview
Table 108. Roche Holding AG Product
Table 109. Roche Holding AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$)
Table 110. Roche Holding AG Recent Development
Table 111. Glaxosmithkline Plc Company Details
Table 112. Glaxosmithkline Plc Business Overview
Table 113. Glaxosmithkline Plc Product
Table 114. Glaxosmithkline Plc Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$)
Table 115. Glaxosmithkline Plc Recent Development
Table 116. Novartis Ag Company Details
Table 117. Novartis Ag Business Overview
Table 118. Novartis Ag Product
Table 119. Novartis Ag Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$)
Table 120. Novartis Ag Recent Development
Table 121. Pfizer, Inc.  Business Overview
Table 122. Pfizer, Inc.  Product
Table 123. Pfizer, Inc.  Company Details
Table 124. Pfizer, Inc.  Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$)
Table 125. Pfizer, Inc.  Recent Development
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type: 2020 VS 2026
Figure 2. Afinitor (Everolimus) Features
Figure 3. Avastin (Bevacizumab) Features
Figure 4. Cabomety (Cabozantinib) Features
Figure 5. Inlyta (Axitinib) Features
Figure 6. Nexavar (Sorafenib) Features
Figure 7. Proleukin (Aldesleukin) Features
Figure 8. Torisel (Temsirolimus) Features
Figure 9. Sutent (Sunitinib) Features
Figure 10. Votrient (Pazopanib) Features
Figure 11. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application: 2020 VS 2026
Figure 12. Hospitals Case Studies
Figure 13. Clinic Case Studies
Figure 14. Others Case Studies
Figure 15. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Report Years Considered
Figure 16. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 17. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Regions: 2020 VS 2026
Figure 18. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Regions (2021-2026)
Figure 19. Porter's Five Forces Analysis
Figure 20. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Players in 2019
Figure 21. Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs as of 2019
Figure 22. The Top 10 and 5 Players Market Share by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in 2019
Figure 23. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 30. Active Biotech Ab Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Active Biotech Ab Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
Figure 32. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Amgen Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
Figure 34. Bayer AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Bayer AG Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
Figure 36. Cipla Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Cipla Limited Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
Figure 38. Roche Holding AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Roche Holding AG Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
Figure 40. Glaxosmithkline Plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Glaxosmithkline Plc Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
Figure 42. Novartis Ag Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Novartis Ag Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
Figure 44. Pfizer, Inc.  Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. Pfizer, Inc.  Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
Figure 46. Bottom-up and Top-down Approaches for This Report
Figure 47. Data Triangulation
Figure 48. Key Executives Interviewed